Navigation Links
AstraZeneca Announces Top-Line Results From OSKIRA-1 Phase 3 Study of Fostamatinib in Rheumatoid Arthritis
Date:4/4/2013

rheumatoid arthritis and an alternative to injectable therapies for patients with an inadequate response to conventional Disease Modifying Anti-Rheumatic Drugs (DMARDs), including methotrexate (OSKIRA-1 and OSKIRA-2) and those with an inadequate response to TNF-α antagonists (OSKIRA-3).

About FostamatinibFostamatinib (previously referred to as R788) is the first oral spleen tyrosine kinase (SYK) inhibitor in development for rheumatoid arthritis. In February 2010, AstraZeneca and Rigel Pharmaceuticals announced a worldwide license agreement whereby AstraZeneca would develop and commercialize fostamatinib.

About Rheumatoid Arthritis (RA)Rheumatoid arthritis is a systemic autoimmune disease whereby the immune system attacks the joints, causing pain, swelling to the surrounding tissue and damage to the cartilage and bone. The disease affects approximately one in 100 people worldwide. 

If not adequately treated, RA can destroy cartilage and bone within joints, leading to serious disability and can be associated with reduced life expectancy. Not all RA patients have a satisfactory response to existing therapies because the disease pathology may differ from one individual to another and a considerable unmet need remains.

In the US alone the total annual societal cost of RA is estimated to amount to $39.2 billion, with even greater indirect costs to individuals and society including costs from diminished work capacity, loss of productivity, loss in earnings and loss in tax contributions.

About Rigel Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Rigel's pioneering research focuses on intracellular signalling pathways and related targets that are critical to disease
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Zacks Bull and Bear of the Day Highlights: Discover Financial Services, POSCO, AstraZeneca, Bayer and Takeda Pharmaceutical
2. AstraZeneca And Cellworks Collaborate To Find New Treatment For Tuberculosis
3. Genpact and AstraZeneca Win Outsourcing Center and SSON Awards
4. AstraZeneca Acquires Neuroscience Assets From Link Medicine
5. AstraZeneca and Leading Academic Scientists to Collaborate on Alzheimers Disease Research
6. Founded by Enlight Biosciences, KNODE partners with AstraZeneca and Other Partners
7. Regulus Therapeutics Forms Strategic Alliance for Discovery, Development and Commercialization of microRNA Therapeutics with AstraZeneca
8. AstraZeneca And The Broad Institute Partner To Advance Discovery Of Antibacterial And Antiviral Agents
9. Isis Pharmaceuticals And AstraZeneca Form Strategic Alliance On RNA Therapeutics For Cancer
10. AstraZeneca Announces Top-Line Results of OSKIRA-4 Phase IIb Study of Fostamatinib as a Monotherapy for Rheumatoid Arthritis
11. AstraZeneca Announces Results From Long-Term Safety Trial Of Naloxegol In Patients With Opioid-Induced Constipation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ) ("Galmed"), ... and commercialization of a once-daily, oral therapy for ... today announced financial results for the 12 months ... 2014 Highlights: , Hosted a key opinion ... Rohit Loomba, MD, MHSc., who discussed the topic ...
(Date:3/31/2015)... March 31, 2015   Unique Pharmaceuticals , a ... complete and the company has initiated sterile compounding operations ... goal as a company is to meet and exceed ... . "Meeting the new regulations is validation of our ... the future of our industry, investing in its continued ...
(Date:3/31/2015)... , March 31, 2015 ... today announced a strategic partnership with Medidata ... for clinical research in life sciences. Offering therapeutic ... CRO has deployed Medidata,s electronic data capture (EDC), ... Biorasi,s Phase I through IV global clinical trial ...
Breaking Medicine Technology:Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 2Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 3Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 4Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 5Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 6Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 7Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 8Unique Pharmaceuticals Launches Sterile Operations under New Federal Guidance 2Unique Pharmaceuticals Launches Sterile Operations under New Federal Guidance 3Biorasi Selects Medidata's Cloud-Based Platform for Optimal Trial Operations 2Biorasi Selects Medidata's Cloud-Based Platform for Optimal Trial Operations 3Biorasi Selects Medidata's Cloud-Based Platform for Optimal Trial Operations 4
... Oct. 3, 2011 Varian Medical Systems (NYSE: ... senior managers to support the company,s ongoing growth and ... Vice President for the company, has been named Chief ... development, production, promotion, and sale of all Varian products ...
...   PLC Medical Systems, Inc. (OTC: PLCSF) today announced ... , October 6, 2011TIME: , 11:00 AM ... "register/ watch event now" button.This will be a live, ... the company questions in real-time both in the presentation ...
Cached Medicine Technology:Varian Medical Systems Announces New Management Positions 2Varian Medical Systems Announces New Management Positions 3Varian Medical Systems Announces New Management Positions 4PLC Medical Systems to Present Webcast Live, at RetailInvestorConferences.com on October 6th 2
(Date:3/31/2015)... Stem cells may provide Crohn’s disease ... – fistulas – according to the results of a ... of STEM CELLS Translational Medicine (SCTM). After receiving an ... are collected from fat tissue, the fistulas in 75 ... eight weeks of their last treatment and remained so ...
(Date:3/31/2015)... 31, 2015 Diane Blackburn-Zambetti is ... the Mesothelioma Applied Research Foundation (Meso Foundation). Blackburn-Zambetti ... Your Health” at the BoRit Asbestos Superfund Citizen ... This program will discuss anatomy, six types of ... diseases, symptoms, treatments, prevention and proper communication with ...
(Date:3/31/2015)... PharmMD CEO Robert Yeager ... newly created, senior executive role of Chief Technology Officer ... delivery of high quality, efficient, reliable, and secure applications, ... momentum as a market innovator for Part D Star ... “We were very strategic in our search for the ...
(Date:3/31/2015)... Mega Photo, from the makers of Slidezilla, have created ... free app brings a new found life to photos and ... masterpieces. Mega Photo provides over a 100 effects for users ... images in 3-D. , Founder Paul Falstad said that ... it has real-time view so users can try out any ...
(Date:3/31/2015)... St. Louis, MO (PRWEB) March 31, 2015 ... April 8, 2015 from 5:00 to 8:00 pm at the ... than 50 hospitals, clinics and groups with career opportunities will ... represented. Attendees will enjoy free hors d’oeuvres and raffle prize ... PracticeMatch says “Denver is an ideal location to hold ...
Breaking Medicine News(10 mins):Health News:Trial Shows Stem Cells Provide Long-Term Relief from Dangerous Crohn’s Side Effect 2Health News:Mesothelioma Foundation to speak at BoRit Asbestos Superfund Citizen Advisory Group Meeting 2Health News:PharmMD Places Victor Mattingly in C-Suite, Company Focused on Medication Therapy Management and Part D Star Ratings 2Health News:New Mega Photo App Launched and Provides the Ultimate Playground for Photos 2Health News:PracticeMatch to Host Physician Career Fair at SpringHill Suites Denver on April 8, 2015 2Health News:PracticeMatch to Host Physician Career Fair at SpringHill Suites Denver on April 8, 2015 3
... ... ... , ... , , , ...
... workshop have been released to address deep-vein thrombosis (DVT) ... estimated to affect nearly 1 million Americans each year. ... representatives from federal health agencies and patient groups, as ... communities appear in the March 9, 2010, ...
... a successful relationship partners shouldn,t go to bed angry. ... that brain activityspecifically in the region called the lateral prefrontal ... in the days following a fight with his or her ... lateral prefrontal cortex are less likely to be upset the ...
... oophorectomy) while performing a hysterectomy is common practice to ... procedure is performed in 55 percent of all US ... year. An article in the March/April issue of t ... ovaries (bilateral oophorectomy) while performing a hysterectomy is common ...
... anxiety, depression and stress lessened, researchers say , TUESDAY, March ... psychological woes in patients with lupus who have high levels ... also helps these patients improve and maintain their quality of ... included 45 patients randomly assigned to a control group or ...
... ... only seven one-hundredths of one percent of the products manufactured by the company. , ... Dinuba, CA (Vocus) March 9, 2010 ... potential salmonella exposure. To date, no salmonella-related illnesses have been reported in conjunction to ...
Cached Medicine News:Health News:South Dakota Students with Asthma Can Breathe Easier After New Law Allows Self-Administered Medications 2Health News:Critical recommendations unveiled: Deep-vein thrombosis and pulmonary embolism 2Health News:Critical recommendations unveiled: Deep-vein thrombosis and pulmonary embolism 3Health News:After a fight with a partner, brain activity predicts emotional resiliency 2Health News:New study questions benefits of elective removal of ovaries during hysterectomy 2
PremierEdge™ Stab Knives - 45°....
PremierEdge™ Stab Knives - 30°....
PremierEdge™ Stab Knives - 22.5°....
Lacrimal Intubation Set w/Retrieval Device. Size: Probes 23g x 4-1/4"....
Medicine Products: